Literature DB >> 3976086

[Effect of calcium antagonists (nifedipine) on nephrocalcinosis and calcium excretion in the rat].

K H Bichler, W L Strohmaier, F Schanz, H J Nelde, I Gaiser, E Schulze, M Schreiber.   

Abstract

An animal model was established to test the effect of a calcium antagonist on nephrocalcinosis, which was induced by an atherogenous diet, and its effect on the excretion of calcium and other parameters relevant for stone formation. With the administration of nifedipine (Adalat), the grade of nephrocalcinosis could be significantly reduced. Furthermore, with nifedipine the excretion of calcium and sodium in the urine was raised, while phosphate and potassium levels were lowered. The excretion of magnesium and citrate, reduced by an atherogenous diet, could be raised significantly with the administration of nifedipine. The pathophysiological mechanisms underlying the effect of nifedipine on nephrocalcinosis and on the excretion of the urine parameters are discussed. Apparently hypercalciuria is the result of a reduced reabsorption of calcium in the tubulus. The inhibitory effect on the genesis of nephrocalcinosis is possibly due to the lower calcium influx into the tubular cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3976086     DOI: 10.1159/000281025

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Effect of verapamil on urinary stone-forming risk factors.

Authors:  Kemal Sarica; Sakip Erturhan; Bulent Altay
Journal:  Urol Res       Date:  2006-12-13

2.  The effect of verapamil and thiazide in the prevention of renal stone formation.

Authors:  A Halabe; N L Wong; R A Sutton
Journal:  Urol Res       Date:  1990

3.  The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy.

Authors:  Kemal Sarica; Yener Inal; Sakip Erturhan; Faruk Yağci
Journal:  Urol Res       Date:  2006-02-04

Review 4.  Recent advances in understanding and managing urolithiasis.

Authors:  Walter L Strohmaier
Journal:  F1000Res       Date:  2016-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.